Arcturus Q3 10-Q: Loss Narrows to $7.4M, $184.8M Cash, CSL Exit Booked
ARCT sits 80% above its 52-week low of $5.5.
Summary
Arcturus' Q3 10-Q confirms the narrowed $7.4M net loss and $184.8M cash balance already reported, and for the first time lays out the full economics of the CSL Seqirus termination and the closed myNEO acquisition.
Key Events · Earnings and Guidance · ARCT
-
Q3 Loss Narrows on Cost Cuts
Net loss was $7.4M ($0.26/share) versus $13.4M ($0.49/share) a year earlier, as R&D fell 27% to $17.0M from $23.3M. Nine-month net loss widened to $58.2M from $36.7M.
-
Cash Down $46.1M Year to Date
Cash and equivalents were $184.8M at September 30, 2026 versus $230.9M at December 31, 2025; nine-month operating cash use was $46.3M. Management cites runway through year-end 2028.
-
CSL Exit Economics Quantified
The August 3, 2026 termination brought a $12.0M cash payment and release of ~$16.0M in R&D credit and unspent development repayment obligations; the ICC arbitration was dismissed and $16.8M of CSL revenue was recognized in Q3.
-
myNEO Deal Closed October 15
Arcturus paid ~$5.0M cash and issued 361,355 unregistered shares, with up to $20.0M of contingent clinical and collaboration milestones, a portion settleable in stock.
Analysis · ARCT · Life Sciences
The headline numbers were already out via the same-day 8-K and press release, but the 10-Q is where the balance sheet and the CSL Seqirus exit become concrete. Cash fell to $184.8M from $230.9M at year-end 2025 — a $46.3M nine-month operating burn — and management still frames runway through year-end 2028, which assumes the cost base stays near the newly reduced level (R&D down 27% year over year to $17.0M in the quarter). The CSL termination is now fully quantified: $12.0M cash in, roughly $16.0M of R&D credit and repayment obligations released, the ICC arbitration dismissed, and $16.8M of revenue recognized in Q3 — which is why the quarter shows revenue growth despite the collaboration ending. Against that, the company has taken on new obligations: single-digit royalties to CSL on future vaccine sales, up to $20.0M of contingent myNEO milestones (partly payable in stock), and up to $80.0M of Thermo Fisher/PPD service commitments for ARCT-032. The $200M ATM remains unused this year, so the dilution lever is intact but unpulled.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARCT was trading at $9.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $266M. The 52-week trading range was $5.50 to $17.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.